# CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

> **NCT02693080** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 19 (actual)

## Conditions studied

- Malignant Lung Neoplasm
- Metastatic Malignant Neoplasm in the Lung
- Non-Small Cell Lung Carcinoma
- Stage IV Lung Cancer

## Interventions

- **DEVICE:** CAPP-Seq
- **DRUG:** Isovue-200
- **RADIATION:** Computed Tomography Perfusion Imaging

## Key facts

- **NCT ID:** NCT02693080
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-19
- **Primary completion:** 2020-04-29
- **Final completion:** 2020-04-29
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02693080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02693080, "CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02693080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*